NVS vs AZN stock comparison
Novartis vs. Astrazeneca · data as of November 13, 2026
Novartis (NVS) has a market value of about $306.3B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Novartis had revenue of $57.4B and Astrazeneca $62.4B.
On our five checks Astrazeneca scores higher: 2.8 out of 5 (average) against 2.0 (weak).
By area, the stronger company is Astrazeneca on value; Astrazeneca on future growth; Astrazeneca on shareholder returns.
Astrazeneca is cheaper on earnings (P/E 26.1 vs. 30.7).
Novartis leads on 7 of the compared lines and Astrazeneca on 16.
Side by side
| NVS | AZN | |
|---|---|---|
| Size and price | ||
| Market cap | $306.3B | $286.0B |
| Share price | $160.50 | $184.45 |
| Score | ||
| Overall score (of 5) | 2.0 | 2.8 |
| Value | 0 | 1 |
| Future growth | 0 | 2 |
| Track record | 4 | 4 |
| Financial health | 3 | 3 |
| Shareholder returns | 3 | 4 |
| Valuation | ||
| P/E (TTM) | 30.7 | 26.1 |
| Forward P/E | 17.0 | 16.5 |
| Price / free cash flow | 21.9 | 46.9 |
| Price / sales | 5.3 | 4.6 |
| EV / EBITDA | 14.4 | 14.7 |
| PEG | 2.02 | 1.20 |
| DCF value vs. price | −9% | −38% |
| Business | ||
| Revenue | $57.4B | $62.4B |
| Net income | $10.0B | $11.0B |
| Free cash flow | $14.0B | $6.1B |
| Net margin | 17.5% | 17.7% |
| Gross margin (5-yr avg.) | 76.4% | 76.8% |
| ROIC (5-yr avg.) | 14.1% | 8.4% |
| Growth | ||
| Revenue growth (1 yr) | 8.4% | 8.6% |
| Revenue growth (5 yrs, per year) | 2.3% | 17.2% |
| EPS growth (5 yrs, per year) | 15.2% | 21.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$39.3B | -$26.0B |
| Dividend yield | 2.95% | 1.74% |
| Shareholder yield | 6.0% | 1.9% |
| Analysts | ||
| Upside to average target | −2% | +13% |
| Consensus rating | Hold | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: NVS TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Novartis or Astrazeneca?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Astrazeneca scores 2.8 out of 5 and Novartis 2.0; the table shows where each one is stronger.
Is Novartis cheaper than Astrazeneca?
On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Novartis at 30.7, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Novartis or Astrazeneca?
Over five years Astrazeneca grew revenue about 17.2% a year and Novartis about 2.3% a year.
Which pays a higher dividend?
Novartis yields 2.95% and Astrazeneca 1.74%.
Full Novartis analysis → Full Astrazeneca analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.